EZH2
41 programs · 41 companies
Programs
41
Companies
41
Active Trials
28
Targeting EZH2
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| DSN-2247 | Daiichi Sankyo | NDA/BLA | AsthmaMM | |
| HAL-9635 | Halozyme | Phase 2/3 | MSObesity | |
| Voxabrutinib | Annexon | Phase 1/2 | CMLTTR Amyloidosis | |
| SLD-1824 | Solid Bio | Phase 2 | NB | |
| Gelibrutinib | Sun Pharma | NDA/BLA | ETMDD | |
| RDY-3640 | Dr Reddy's | Preclinical | ObesityHNSCC | |
| Rimanesiran | Alector | Phase 1 | Pompe | |
| Nidafutibatinib | Precision Bio | NDA/BLA | IgANAsthma | |
| Datolucimab | Upstream Bio | Approved | Rett | |
| Capitapinarof | ENDRA Life Sciences | Phase 3 | Bladder CaADHD | |
| Daratenlimab | Theratechnologies | Phase 1 | CKD | |
| Gozederotide | Aclaris Therapeutics | Preclinical | CMLMM | |
| Elrazasiran | Inhibrx Biosciences | NDA/BLA | Dravet | |
| ANT-256 | AN2 Therapeutics | NDA/BLA | Dravet | |
| Ribomavacamten | G1 Therapeutics (Licella) | Phase 3 | MesoFabry | |
| ACE-6753 | Acer Therapeutics | Phase 2/3 | AsthmaPV | |
| 255-7731 | Hua Medicine | Phase 1 | RBWilms | |
| Semarasimod | Lenz Ther | Phase 1/2 | HCCSMA | |
| BBI-8786 | Bridgebio | Phase 2 | MDD | |
| Rilunaritide | Targovax | Phase 2 | Melanoma | |
| Pexatenlimab | Meiji Pharma | Approved | Ewing Sarcoma | |
| Zoriderotide | Hanmi Pharma | Phase 3 | T2D | |
| TOR-3576 | Torrent Pharma | NDA/BLA | Bladder CaOvarian Ca | |
| MOR-1300 | Morphic (Lilly) | Phase 1/2 | CholangiocarcinomaIPF | |
| AVR-5957 | Anteris Tech | NDA/BLA | MDDMCC | |
| NAN-2606 | Nordic Nano | Phase 1 | BCCT2D | |
| URG-417 | UroGen | NDA/BLA | CSUGIST | |
| OGN-4949 | Organon | Phase 1/2 | Urothelial Ca | |
| POL-5703 | Polyphor | Approved | Migraine | |
| Teraosocimab | Orion Pharma | Phase 1 | FL | |
| INS-860 | Insud Pharma | Phase 2 | Urothelial CaWilms | |
| PRI-IIT-296 | Princess Margaret | NDA/BLA | SCD | |
| CAM-IIT-544 | CAMS Peking Union | NDA/BLA | Wilms | |
| FUD-IIT-297 | Fudan Cancer Hosp | Preclinical | Celiac | |
| AII-IIT-782 | AIIMS New Delhi | Phase 2/3 | ALS | |
| INT-6808 | Intas Pharma | Approved | MS | |
| 153-2292 | 3SBio | Preclinical | PNH | |
| AVT-4398 | Avantor | Phase 3 | MMAsthma | |
| Fixazanubrutinib | Zoetis | Preclinical | AsthmaEwing Sarcoma | |
| Ivosotorasib | Elanco | Phase 2/3 | LNSCD | |
| Pexalucimab | Amyris | Phase 3 | RACKD |